Suchergebnisse - "Weis, Nina"

PubPharm (14)

1

Amantadine for COVID-19 treatment (ACT) study : a randomized, double-blinded, placebo-controlled clinical trial

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Weis, N. | Bollerup, S. | Sund, J. | +6

2

Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals

enthalten in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | 2023

von Sølund, C. | Pedersen, M. | Fahnøe, U. | +5

3

Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide

enthalten in: Nature | 2023

von Sherwood, A. | Rivera-Rangel, L. | Ryberg, L. | +25

4

Incidence, prevalence and risk factors for hepatitis C in Danish prisons

enthalten in: PloS one | 2019

von Søholm, J. | Holm, D. | Mössner, B. | +6

5

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

6

Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail

enthalten in: PloS one | 2018

von Neesgaard, B. | Ruhwald, M. | Krarup, H. | +1

7

Analytical and clinical performance of the Hologic Aptima HCV Quant Dx Assay for the quantification of HCV RNA in plasma samples

enthalten in: Journal of virological methods | 2017

von Schønning, K. | Pedersen, M. | Johansen, K. | +4

8

Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark

enthalten in: BMC infectious diseases | 2017

von Wessman, M. | Thorsteinsson, K. | Jensen, J. | +9

9

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY) : a randomised, open-label phase 2 trial

enthalten in: Lancet (London, England) | 2015

von Sulkowski, M. | Hezode, C. | Gerstoft, J. | +20

CommentIn: Lancet. 2015 Mar 21;385(9973):1050-2. - PMID 25468162

10

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

enthalten in: Gastroenterology | 2015

von Dore, G. | Lawitz, E. | Hézode, C. | +24